


Osteoporosis

Testing and Treatment for Home Health and Long Term Care Patients with a Prior Fracture

- Recommended lab tests:
 - Serum Calcium, Creatinine (calculate GFR^{*}), Alkaline Phosphatase
- Supplemental lab tests:
 - Serum 25(OH) vitamin D
 - Intact PTH, if calcium is elevated
 - TSH, if on thyroid medication
 - SPEP, if clinical suspicion for myeloma



*Glomerular Filtration Rate (GFR) = $\frac{(140 - \text{age}) \times (\text{weight in kg}) \times 0.85 \text{ for women}}{(\text{creatinine} \times 72)}$

**If serum 25(OH) vitamin D cannot be measured or is < 30 ng/mL (75 nmol/L)

[†]See other side of card for list of measures (Item #4)

[‡]Assuming no contraindications (e.g. GFR < 30-35 mL/min for BPs, male sex for Evista)

BP – bisphosphonate; DXA – dual energy X-ray absorptiometry; IU – international unit; IV – intravenous; PTH – parathyroid hormone; SERM – selective estrogen receptor modulator; SPEP – serum protein electrophoresis; TSH – thyroid-stimulating hormone; Tx – treatment

Developed by consensus: Jeffrey R. Curtis MD MPH¹, Kellie L. Flood MD¹, Ryan C. Outman MS¹, Kenneth G. Saag MD MSc¹, Amy H. Warriner MD¹, Cathleen Colón-Emeric MD², Kenneth W. Lyles MD², Sarah D. Berry MD MPH³, Nelson B. Watts MD⁴, S. Bobo Tanner MD⁵

¹University of Alabama at Birmingham, ²Duke University and the Durham VA Medical Center GRECC, ³Harvard Medical School, ⁴University of Cincinnati Bone Health and Osteoporosis Center,

⁵Vanderbilt University

1. Do I need a DXA to start treatment?

- No. For many home health or long term care patients, obtaining a DXA is infeasible. In the absence of major trauma (e.g. a motor vehicle accident), if patients over age 50 have had a fracture, they have osteoporosis and can be treated with prescription medication. Medicare recommends that post-fracture patients either be screened with a DXA OR treated with a prescription medication within 6 months of fracture.

For patients for whom obtaining a DXA is infeasible, the following table¹ provides the ten-year risk of a major osteoporotic fracture (e.g. hip, clinical vertebral, proximal humerus, distal forearm) among patients with a prior fracture and normal body mass index.

Risk Factors	Caucasian Female			Caucasian Male		
	Age 65	75	85	65	75	85
None	26%	46%	51%	16%	24%	26%
Corticosteroids	39%	61%	60%	24%	33%	32%
Currently smoking	27%	48%	50%	16%	24%	25%

2. Why is serum 25-hydroxyvitamin D (OHD) important and what is a healthy level?

- Increases calcium absorption²
 - Decreases fall risk⁴
 - Decreases fracture risk³
- A threshold of ≥ 30 ng/mL (75 nmol/L) is the serum 25(OH)D concentration at which older men and women are at a lower risk of fracture⁶. A desirable range is 30-60 ng/mL. Many “healthy” adults are too low.

3. How much vitamin D should I give?

- If vitamin D cannot be measured or is < 30 ng/mL (75 nmol/L):
 - 50,000 IU of D₂ (ergocalciferol) once a week for 12 weeks, thereafter 50,000 IU of D₂ (ergocalciferol) once or twice monthly indefinitely
 - If vitamin D is ≥ 30 ng/mL (75 nmol/L):
 - 50,000 IU of D₂ (ergocalciferol) once or twice monthly indefinitely
 - Vitamin D toxicity is rare. Doses as high as 10,000 IU of vitamin D₃ per day for up to 5 months have not resulted in toxicity⁷. Persons spending long amounts of time in the sun (e.g. migrant farm workers, lifeguards) have vitamin D levels in the 150 ng/mL range without any adverse effect⁸.

4. What fall risk prevention measures should I consider?

- Home safety evaluation by home health occupational therapist: if homebound, or home safety checklist (see www.cdc.gov/ncipc/falls/FallPrev4.pdf for examples)
- Physical therapy referral for proximal muscle strengthening, balance training and ambulation aids (walker, cane, etc.)
- When possible, taper off sedatives and psychoactive medications
- Vision test
- Alcohol cessation
- If a patient has symptoms of orthostasis, recommend care on rising quickly from supine/seated position

5. What is the relative risk reduction (RR) for fractures that I can expect with prescription drugs for osteoporosis?

Drug Class	Vertebral Fracture RR (% , 95% CI)*	Non-Vertebral Fracture RR (% , 95% CI)*	Hip Fracture RR (% , 95% CI)*
	Vertebral Fracture RR (% , 95% CI)*	Non-Vertebral Fracture RR (% , 95% CI)*	Hip Fracture RR (% , 95% CI)*
Bisphosphonates			
• Actonel® (risedronate)	39 (24-50)	20 (10-28)	26 (6-41)**
• Boniva® (ibandronate)	52 (29-68)	Not significant	Not significant
• Fosamax® (alendronate)	45 (31-57)	23 (8-36)*	53 (15-74)
• Reclast® (zoledronic acid)	70 (62-76)	25 (13-36)	41 (17-58)
Parathyroid Hormone (PTH)			
• Forteo® (teriparatide)	65 (45-78)	35 (2-57)	Not significant
Selective estrogen-receptor modulators (SERMs)			
• Evista® (raloxifene)	30 (14-44)	Not significant	Not significant
Calcitonin-salmon			
• Fortical®, Miacalcin® (calcitonin)	36 (4-57)	Not significant	Not significant

*Data were obtained from product labelling and the Cochrane Collaboration (<http://www.cochrane.org>) and are not from head to head studies. Comparative efficacy is not implied. **Evidence for effect but not an FDA-approved indication.

- Bischoff HA, Stadelman HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. *J Bone Miner Res* 2003; 18(2):343-351.
- Dawson-Hughes B, Heaney RP, Dowell MS, Hail CA, Bilezikian JP, et al. Estimation of optimal vitamin D status: Osteoporos Int 2005; 16(7):71-76.
- Heaney RP, Dowell MS, Hail CA, Bilezikian JP, et al. Fracture prevention: a meta-analysis of randomized controlled trials. *JAMA* 2005; 293(18):2257-2264.
- Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC et al. Effect of vitamin D on falls: a meta-analysis. *J Am Geriatr Soc* 1999; 47:1999-2006.
- Vieh R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* 1999; 69:842-856.